Case Report
Interstitial lung disease associated to erlotinib treatment: a case report
-
* Corresponding author: Yolanda del Castillo castilloduran@hotmail.com
Unidad de Cuidados Intensivos, Hospital de Sant Pau i Santa Tecla, Rambla Vella, 14. 43003, Tarragona, Spain
Cases Journal 2010, 3:59 doi:10.1186/1757-1626-3-59
Published: 12 February 2010Abstract
Introduction
Few cases of pulmonary toxicity related to epidermal growth factor receptor-targeted agents have been described.
Case presentation
We report a case of a 63-year-old white male with stage IV non-small cell lung cancer treated with erlotinib who developed a interstitial lung disease.
Conclusion
Respiratory symptoms during treatment with erlotinib should alert clinicians to rule out pulmonary toxicity. Early erlotinib withdrawal and corticoid administration were successful.